Scarica l'app Stockscreener
58.25
2.80%
-1.68
Dopo l'orario di chiusura:
59.30
1.05
+1.80%
Precedente Chiudi:
$59.93
Aprire:
$60.01
Volume 24 ore:
3.47M
Relative Volume:
1.79
Capitalizzazione di mercato:
$4.37B
Reddito:
-
Utile/perdita netta:
$-275.16M
Rapporto P/E:
-14.97
EPS:
-3.89
Flusso di cassa netto:
$-221.15M
1 W Prestazione:
+1.43%
1M Prestazione:
+60.25%
6M Prestazione:
+47.39%
1 anno Prestazione:
+18.35%
Intervallo 1D:
$57.72
$60.20
Intervallo di 1 settimana:
$54.89
$62.00
Portata 52W:
$28.21
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Nome
Springworks Therapeutics Inc
Settore
Industria
Telefono
203-883-9490
Indirizzo
100 WASHINGTON BOULEVARD, STAMFORD, CT
Confronta SWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
58.25 | 4.37B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-20 | Iniziato | Evercore ISI | Outperform |
| 2024-02-05 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-03-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-08 | Iniziato | Cowen | Outperform |
| 2019-10-08 | Iniziato | Goldman | Buy |
| 2019-10-08 | Iniziato | JP Morgan | Overweight |
| 2019-10-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Springworks Therapeutics Inc Borsa (SWTX) Ultime notizie
SpringWorks Therapeutics' (SWTX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Principal Financial Group Inc. Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect - MSN
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from Wedbush - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Announces Earnings Results, Misses Estimates By $0.38 EPS - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Sets New 1-Year HighTime to Buy? - MarketBeat
What the Options Market Tells Us About SpringWorks Therapeutics - Benzinga
Daniel Lynch Sells 400 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock - MarketBeat
Insider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells 10,672 Shares of Stock - MarketBeat
SpringWorks teams with jewelry designer Jennifer Fisher for desmoid tumors push - MM+M Online
Top 3 Health Care Stocks You May Want To Dump In February - Benzinga
SpringWorks stock hits 52-week high at $61.4 amid growth optimism - Investing.com Nigeria
SpringWorks Therapeutics jumps after results, conference call cancellation - MSN
Sector Update: Health Care Stocks Rise Thursday Afternoon -February 20, 2025 at 01:57 pm EST - Marketscreener.com
SpringWorks stock hits 52-week high at $61.4 amid growth optimism By Investing.com - Investing.com South Africa
SpringWorks Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Risky weight loss, grad school acceptance cuts, and more major biotech news of the day - STAT
SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics rises as canceled earnings call raises buyout hopes - TradingView
Springworks Therapeutics Q4 Net Loss Narrows -February 20, 2025 at 07:01 am EST - Marketscreener.com
SPRINGWORKS THERAPEUTICS Earnings Results: $SWTX Reports Quarterly Earnings - Nasdaq
Earnings Flash (SWTX) Springworks Therapeutics Posts Q4 Net Loss $-1.04 a Share, vs. FactSet Est of $-0.71 Loss - Marketscreener.com
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
SpringWorks Therapeutics Reports Fourth Quarter and Full - GlobeNewswire
Can SpringWorks' Dual Drug Strategy Transform Its Financial Future? Q4 Results Reveal Key Insights - StockTitan
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap DownWhat's Next? - MarketBeat
(SWTX) Trading Signals - Stock Traders Daily
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
Why SpringWorks Therapeutics, Inc. (SWTX) is the Best Performing Healthcare Stock So Far in 2025 - Insider Monkey
SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors - TipRanks
From Fashion to Fighting Rare Tumors: How This Designer's Personal Battle Could Help Thousands - StockTitan
Here's What Could Help SpringWorks Therapeutics (SWTX) Maintain Its Recent Price Strength - MSN
Wedbush Issues Positive Outlook for SWTX Earnings - MarketBeat
SpringWorks Therapeutics' SWOT analysis: biotech stock faces growth amid losses - Investing.com
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics - GlobeNewswire Inc.
Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles - substack.com
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Analysts Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Target Price at $70.83 - Defense World
Fiera Capital Corp Decreases Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Springworks Therapeutics chief people officer sells shares worth $1.6 million - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells $2,558,400.00 in Stock - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch Sells 175,000 Shares - MarketBeat
Spring Works shares rise on raised price target to $66 - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Buy Rating from HC Wainwright - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Springworks Therapeutics Inc Azioni (SWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Springworks Therapeutics Inc Azioni (SWTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Islam Saqib | Chief Executive Officer |
Feb 14 '25 |
Sale |
59.92 |
10,672 |
639,490 |
1,063,953 |
| LYNCH DANIEL | Director |
Feb 14 '25 |
Sale |
60.00 |
400 |
24,000 |
130,544 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):